All figures shown in the chart above are for the trailing 12 month (TTM) period

Revenue exceeded analyst estimates by 1.4%. Earnings per share (EPS) missed analyst estimates by 16%.

Looking ahead, revenue is forecast to grow 5.7% p.a. on average during the next 3 years, compared to a 5.0% growth forecast for the Pharmaceuticals industry in the United Kingdom.

Performance of the British Pharmaceuticals industry.

The company's share price is broadly unchanged from a week ago.

We don't want to rain on the parade too much, but we did also find 2 warning signs for AstraZeneca that you need to be mindful of.